Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3M | 11M | 0 | 13M | 0 |
| Gross Profit | 3M | 11M | -27M | 9M | -3M |
| Operating Income | -42M | -26M | -46M | -44M | -54M |
| EBITDA | -42M | -24M | -41M | -42M | -51M |
| Net Income | -242M | -64M | -43M | -36M | -53M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0101
-24.63% today
1Y Change
-15.42%
Window
Jun 20, 2025 → Jun 9, 2026
Coverage: 162 bars · Jun 20, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Surrozen, Inc. (SRZNW) is a Healthcare stock with a market cap of $250.00M and listed on NASDAQ. The stock last traded around $0.01 and down 15.4% across the available one-year price window (Jun 20, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of -67.4%, EPS growth of -49.4%, a dividend yield of 0.0%. What stands out right now is revenue -67.4%, EPS -49.4%, free cash flow -72.0% with operating margin -1210.6% and ROIC -46.7%. Valuation already assumes a fairly strong business story at price/sales 72.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SRZNW price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SRZNW
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SRZNW Max Drawdown
-81.33%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SRZNW and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
-100.0% YoY
FY Net Income
-$52.5M
-45.8% YoY
Free Cash Flow
-$50.1M
-11.6% YoY
Revenue Growth
-67.4%
EPS Growth
-49.4%
Gross Margin
98.7%
Net Margin
-6960.8%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3M | 11M | 0 | 13M | 0 |
| Gross Profit | 3M | 11M | -27M | 9M | -3M |
| Operating Income | -42M | -26M | -46M | -44M | -54M |
| EBITDA | -42M | -24M | -41M | -42M | -51M |
| Net Income | -242M | -64M | -43M | -36M | -53M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 89M | 35M | 36M | 25M | 33M |
| Total Assets | 99M | 48M | 46M | 89M | 137M |
| Total Liabilities | 286M | 70M | 8M | 13M | 27M |
| Shareholder Equity | -188M | -21M | 38M | 76M | 110M |
| Total Debt | 7M | 8M | 3M | 6M | 8M |
| Net Debt | -83M | -26M | -33M | -19M | -25M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
49M
-10.6% YoY
Capital Expenditures
1M
-74.3% YoY
Free Cash Flow
50M
-11.6% YoY
Key ratios
Gross Margin
98.7%
Operating Margin
-1210.6%
Net Margin
-6960.8%
ROE
610.8%
Debt / Equity
-0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.